| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| License revenue | 10 | |||
| Research and development | 19.639 | |||
| General and administrative | 3.689 | |||
| Total operating expenses | 23.328 | |||
| Loss from operations | -13.328 | |||
| Interest income | 0.862 | |||
| Other expense, net | 0.009 | |||
| Total other income, net | 0.853 | |||
| Net loss | -12.475 | |||
| Earnings per share, basic | -8.07 | |||
| Earnings per share, diluted | -8.07 | |||
| Weighted average number of shares outstanding, basic | 1,545,010 | |||
| Weighted average number of shares outstanding, diluted | 1,545,010 | |||
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)